APG Health is excited to announce that APG Research is currently enrolling Adults with Depression and Obsessive-Compulsive Disorders in Clinical Trials. If you or someone you know is interested in participating, please call or text 407-808-1875 or discuss with your provider to learn more about our studies. Compensation for time and travel will be provided for qualified participants
ADHD & Autism
APG Health is excited to announce the opening of the APG Research Child and Adolescent Division specializing in Autism Spectrum Disorder and ADHD. Please inquire today by calling 407-808-1875 to learn about our current clinical trials.
Existing Patients
Existing Patient Portal
Don’t have a portal account? Existing patients please email portalrequest@apghealth.com
New Patients
New Patient Appointment
Click below to begin the process if you are interested in becoming a new patient!
APG uses email strictly for the following purposes only:
- Receive copies of ID cards and Insurance Cards
- Receive Medical Records for Clinician Review from previous providers, hospitals, or other specialists
Please do not email refill requests, medical status updates, and/or appointment requests. Please message your clinician using your patient portal or call our office at 407-423-7149. If your request is urgent or an emergency, please go to your nearest emergency room or behavioral health hospital.
Now Offering Telemedicine Appointments
For new & existing patients!
APG Healthcare is Now REMS Certified to Provide SPRAVATO™ (esketamine) CIII Nasal Spray Medication for Adults with Treatment-Resistant Depression
Learn More
We are now Risk Evaluation and Mitigation Strategy (REMS) certified to provide SPRAVATO™ (esketamine) CIII, a nasal spray approved for use in conjunction with an oral antidepressant in adults with treatment-resistant depression (TRD).1 People who are currently struggling with major depressive disorder (MDD) may have TRD if they have not responded adequately to at least two different antidepressants of adequate dose and duration in the current depressive episode.2
As a certified treatment center, our medical staff have been trained to prescribe, dispense and administer SPRAVATO™and have established processes and procedures in accordance with the REMS. A healthcare provider will provide direct supervision as the patient self-administers SPRAVATO™ and will monitor every patient after every dose for at least two hours for resolution of sedation and dissociation and changes in vital signs. SPRAVATO™ must never be dispensed directly to a patient for home use.
Additionally, all patients will require transportation from APG Healthcare following the observation period,as they should not drive or operate machinery until the day after a treatment session, following a restful sleep.
For more information regarding administration, REMS requirements, or other related questions, please contact one of our administrative assistants at 407-423-7149.
Because of the risks for sedation, dissociation(feeling disconnected from yourself, your thoughts, feelings, space and time),and abuse and misuse, SPRAVATO™ carries a Boxed WARNING and is only available through a restricted program called the SPRAVATO™ Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO™ can only be administered at healthcare settings certified in the SPRAVATO™ REMS Program and to patients enrolled in the program.
For more information on SPRAVATO™, please refer to the manufacturer’s Prescribing Information and Medication Guide or visit www.SPRAVATO.com. If you are a patient, please speak to your healthcare provider for more information.
For more information on SPRAVATO™, please refer to the manufacturer’s Prescribing Information and Medication Guide or visit www.SPRAVATO.com. If you are a patient, please speak to your healthcare provider for more information.
